A genetically modified pig kidney kept a 66-year-old man off dialysis for a record nine months, marking the longest survival yet for a pig kidney transplanted into a living person and the first time such an organ successfully served as a bridge to a later human transplant. The Guardian reports: Tim Andrews was seriously ill with end-stage kidney disease caused by type 2 diabetes and had only a 9% chance of receiving a human kidney within five years, against a more than 40% risk of dying or being removed from the waiting list. Kidney transplantation provides the best survival and quality of life for patients with end-stage kidney disease, but global demand for human organs far exceeds supply. Surgeons in the US successfully transplanted a kidney from Wilma, a Yucatan miniature pig, into Andrews, after genetically engineering it to be compatible with his immune system. The kidney kept Andrews free of dialysis for a record nine months, the longest period ever recorded, before it began failing and he received one from a dead human donor. It was also the first time a pig's kidney had been used as a temporary "bridge" to a human transplant. The breakthrough has been detailed in the journal Lancet.

Read more of this story at Slashdot.

CNN reports that "A one-time snip of a key gene lowered heart-clogging cholesterol by about 50% over an entire year with no adverse effects, scientists have reported." The overwhelmingly positive results were found in four people who had taken the highest dose of the experimental treatment during a pilot study published in The New England Journal of Medicine in November 2025. That study was extremely small — only 15 patients with dangerously high cholesterol that did not respond to medication. The research was designed to test the safety of five different doses of a gene-altering infusion delivered by CRISPR-Cas9, a biological scissor which cuts a targeted genetic location to modify or turn a gene on or off. "If you'd asked me 15 years ago if we could have done something like this, I would have thought you were crazy," senior study author Dr. Steven Nissen, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic in Ohio, told CNN previously. An update on the study, published Friday in NEJM, appears to answer a key question: Does the intervention last? "Is something like this truly a one and done? That was always the question," said lead study author Dr. Luke Laffin, a preventive cardiologist at Cleveland Clinic's Heart, Vascular & Thoracic Institute. "This new data is essentially saying that the decreases in LDL cholesterol and triglycerides we saw at 60 days after treatment have lasted over a year," Laffin said. "In people who took the highest dose, the reduction seems durable and safe...." If larger clinical trials show similar results, the procedure could be a game changer for young people with severe disease, preventive cardiologist Dr. Ann Marie Navar, an associate professor of cardiology at UT Southwestern Medical Center in Dallas, told CNN previously. "If you're 20 and you have really high cholesterol, it may make a lot more sense to have a one-time treatment that doesn't require you to have to take a pill every single day or shot every two weeks for the next 60 years," said Navar, who was not involved in the study. "The potential for this is just enormous." Being born with this mutation naturally "drastically lowers or even eliminates a person's risk for heart disease," the article points out. And the study's senior author adds "now that CRISPR is here, we have the ability to change other people's genes so they too can have this protection."

Read more of this story at Slashdot.

An anonymous reader quotes a report from The Guardian: A common sweetener used in products such as chewing gum, toothpaste, jam, yoghurts and ice-cream has been linked to an increased risk of strokes, heart attacks and death. Xylitol is a sugar alcohol present in some natural foods in very low amounts. It is also added -- often in amounts 1,000 times higher -- to artificially sweeten foods, beverages and oral care products. Despite its growing use, the long-term health impacts of xylitol have never been widely studied. In the largest study of its kind, researchers found high blood levels of xylitol were associated with an increased risk of major adverse cardiovascular events. The findings were presented in Munich at the European Society of Cardiology (ESC) annual congress, the world's largest heart conference. Researchers looked at 17,710 people and compared the 25% with the highest levels of xylitol in their blood against the 25% with the lowest. Those who had the highest amount were 57% more likely to die or suffer a heart attack or stroke, than those with the least, within six years. Even after 30 years, they were still 18% more likely to have suffered one of these cardiac events. Taken with data from the middle quartiles, the results from both cohorts suggested a dose-dependent relationship: the higher the xylitol blood levels, the higher the cardiovascular event rate. Furthermore, the researchers showed that there was consistent increase in cardiovascular events with xylitol irrespective of baseline characteristics, such as age and sex. The researchers also highlighted that the association was independent of underlying factors such as body mass index, hypertension, diabetes and lipid levels, which might predispose people to low-calorie products.

Read more of this story at Slashdot.

A French court has for the first time recognized cosmic radiation as a contributing occupational factor in a flight attendant's breast cancer, alongside passive smoking and years of night work. The landmark ruling could open the door to similar claims from other aircrew, as research continues to link long-term high-altitude flying with elevated exposure to radiation-related cancers. The BBC reports: Sophie Lainault, a 59 year-old former stewardess on Air France, sought to have her cancer recognized as an occupational disease, brought on by conditions at work. This has now been confirmed in a landmark court ruling in the southwestern town of Bayonne, which said that cosmic radiation was one of three carcinogenic hazards arising from her profession. [...] As stewardess and later purser on Air France airliners, Lainault clocked up 12,600 flight hours between 1989 and 2019. More than half of these were at night. Many long-distance high-altitude flights from Paris would have taken her near the North Pole, where exposure to radiation from space -- strictly speaking particles from the sun and other stars -- is the most intense. A study this month at the Harvard Medical School in the US found that flight attendants and pilots had the highest level of radiation-related cancer deaths among more than 500 different professions. In all, about 6.9% of deaths among flight attendants and 6.7% of deaths among pilots were from radiation-related cancers, according to the analysis. These proportions were higher than for other professions including nuclear technologists, who are routinely exposed to radiation from non-cosmic sources yet placed 12th on the list, the authors said. "In France the link between breast cancer and certain hazards has been established for a number of professions, such as nurses ... but this is the first time for an air-hostess," said Lainault's lawyer Elisabeth Leroux.

Read more of this story at Slashdot.

The FDA has authorized the first wearable in the U.S. to continuously monitor ketone levels and the first device globally to track both ketones and glucose together in a single system. From a report: [Abbott's] Libre Duo 10 Day continuously measures both glucose and ketone levels in the fluid just beneath the skin every minute, day and night. Readings are transmitted wirelessly to a compatible smartphone, where users can view current glucose and ketone levels and whether those values are trending up or down. The device also can send automatic alerts if ketone levels reach a concerning threshold. The FDA noted that ketone information should be interpreted in the context of glucose readings and symptoms. Ketones are produced when the body uses fat instead of glucose for energy. When ketone levels rise too high, patients with diabetes can develop diabetic ketoacidosis (DKA), a serious complication that can progress quickly and become life-threatening without prompt treatment. Until now, patients who needed ketone monitoring had to test separately using methods that provided a single measurement at one point in time. Those tests could not show whether ketone levels were rising or falling. For patients with diabetes -- particularly those at higher risk for DKA -- continuous glucose and ketone monitoring may provide earlier warning of metabolic deterioration and support timelier sick-day management, hydration, insulin adjustment, and escalation of care when clinically appropriate.

Read more of this story at Slashdot.

Moderna and Merck say their personalized mRNA melanoma vaccine significantly reduced both cancer recurrence and spread in a late-stage trial. The treatment could reach patients as soon as next year if regulators approve it. Reuters reports: Moderna developed the vaccine with Merck and tested it together with immunotherapy drug Keytruda, a widely used treatment for melanoma. [...] This is the first positive late-stage trial result for an mRNA cancer vaccine, which trains a patient's immune system to fight tumors by targeting specific mutations in those cells and the first such study to show that adding a treatment to Keytruda worked better than that therapy alone. Similar approaches are being tested against lung, breast and pancreatic cancers. [...] The cancer treatment combines Merck's Keytruda with a made-to-order mRNA vaccine from Moderna that is based on an analysis of mutations found in the patients' own tumors. The trial enrolled 1,137 high-risk patients with stage IIB-IV melanoma that had been surgically removed. Volunteers were randomized to receive up to nine doses of Keytruda plus the personalized vaccine or Keytruda alone for about one year. The companies said no new safety signals have emerged in the trial. In January, the companies announced results of a mid-stage trial of the treatment showing that it reduced the risk of recurrence or death by 49% after five years. Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, said the Moderna results could signal a new era for treating solid-tumor cancers. "The positive hit here leads us into truly this next phase in immunotherapy," Knudsen said. "This is an auspicious start -- this is where things begin." Moderna shares more than doubled on the news, adding about $30 billion to its market value.

Read more of this story at Slashdot.

A study of more than 64,000 people born around the end of Britain's postwar sugar rationing found that those exposed to less sugar during their first 1,000 days had lower rates of five cancers decades later, including roughly 69% lower liver cancer risk and 36% lower breast cancer risk. They also "showed signs of slower biological aging" and "continued to consume less sugar and had healthier diets overall," according to the authors of a new study published in The Conversation. From the report: After the second world war, sugar remained rationed in Britain for several years. But in September 1953, rationing ended and people started eating a lot more sugar. Consumption nearly doubled. This meant that children born just a few months apart had very different levels of sugar exposure both in the womb and during early childhood. For our study, we used data from over 64,000 people born in Britain between 1951 and 1956. Those born earlier spent a larger share of their first 1,000 days under sugar rationing, while those born later experienced progressively less of it. [...] What is most surprising, however, is not the cancer results or the biological markers of ageing. It's how early-life sugar exposure continued to affect people's diets even 50 years later. We found that people who experienced sugar rationing early in life still consumed less sugar in adulthood, around age 50. They also ate less overall, and their diets were healthier and more diverse. This suggests that the level of sweetness people are exposed to very early in life may shape their taste preferences for a long time.

Read more of this story at Slashdot.

An anonymous reader quotes a report from The Guardian: Miniature human organs and other tissues are to be grown from NHS patients' cells in a drive to improve medicine testing and reduce the number of animals used in drug development. Scientists will use the clumps of tissue to learn how diseases vary between patients, helping them identify which treatments are best for different people based on the particular pathology underlying their condition. The move marks a shift away from the traditional use of animals as models for human disease, towards what researchers believe will be more accurate and reliable tests based directly on human tissues. Researchers have been growing tiny clumps of human organs, known as organoids, for more than a decade. Tests show that pieces smaller than a millimeter can mirror key features of full-scale organs and tissues, including how they falter with disease and respond to drugs. Armed with organoids grown from diseased human tissues, scientists can investigate whether new drug candidates reverse pathological changes in all or a subset of patients, and quickly identify ineffective drugs early in the process. Historically, more than 90% of drugs that clear animal testing go on to fail in human trials, raising questions about the value of the tests. US and European medicines regulators now encourage other approaches if available. "It's going to have a major impact on the numbers of animals used and the way we develop new drugs in the future," said Matthias Zilbauer, a clinical professor of paediatric gastroenterology at the Cambridge Stem Cell Institute. "We're not saying there won't be any animal use in the near or foreseeable future, because there are still certain issues that cannot be tested in these new models, but the reduction is very real." "A lot of human diseases either do not occur in animals or occur in a different way because they're not human," added Zilbauer. "We want tests and models that can tell us which treatments work, and in what patients, and a mouse cannot tell us that."

Read more of this story at Slashdot.

Longtime Slashdot reader sbinning shares a press release: The U.S. Department of Veterans Affairs announced the launch of a new clinical trial to evaluate the effectiveness and safety of psilocybin to treat major depression in Veterans, including those with concurrent PTSD. The new trial comes after a recent executive order on "Accelerating Medical Treatments for Serious Mental Illness," which aims to increase clinical trial participation and accelerate innovative research models and drug approvals for psychedelic drugs. [...] The randomized, controlled trial will enroll Veterans diagnosed with treatment-resistant major depressive disorder, with or without concurrent PTSD, and will compare outcomes between two psilocybin dosage levels. The study will also assess participants' levels of depression before and after treatment, tolerability of side effects, and overall patient-reported depression. [...] In addition to this trial, VA is involved in 20 active clinical trials focused on psychedelic therapies for mental health conditions. All VA research -- including research into psychedelics -- is conducted under strict safety protocols and in full compliance with federal guidelines.

Read more of this story at Slashdot.

An anonymous reader quotes a report from the BBC: England is on track to become one of the first countries in the world to eliminate hepatitis C, a dangerous virus that attacks the liver, figures show. The target of treating 80% of all known cases has already been met, and deaths from the virus have fallen by 36% in the last decade, just short of what is needed by 2030. Taking antiviral tablets for 8 to 12 weeks can cure more than 95% of cases. Initiatives including A&E blood tests, GP registration testing and free at-home tests have helped to find people who were previously undiagnosed, says NHS England. NHS England says that since 2015, more than 100,000 people have been diagnosed and treated for hepatitis C, meaning the country is already meeting that target. Another goal -- a 65% reduction in hepatitis C-related mortality compared with 2015 levels -- has yet to be met, but might be before the 2030 target date. Around 50,200 adults are living with hepatitis C, figures for England in 2024 suggest. Estimates indicate 84.6% of those living with hepatitis C have been diagnosed -- just short of the 90% target. The Hepatitis C Trust says England is "on the cusp" of one of the most significant public health achievements in our country's history.

Read more of this story at Slashdot.

alternative_right shares a report from ScienceAlert: [I]n a new study published in the Journal of Cognitive Neuroscience, researchers from Georgetown University Medical Center in the U.S. have revealed that we can put certain tasks on autopilot in a way that enables something closer to true multitasking. Driving is the perfect example: When you take your test, your entire mental and physical energy is concentrated on executing the right combinations of movements and thoughts. After a decade behind the wheel, the brain is no longer consciously thinking everything through in great detail. In the new study, the researchers found that after extensive practice, the brain can effectively reroute some tasks around the brain's main computing center -- like a bypass road around a city -- to reduce mental overload and improve multitasking capability. "We have another stepping stone in our understanding of how the brain learns," says neuroscientist Maximilian Riesenhuber, senior author of the study. "The encouraging part is that you really can learn to multitask. There is actually a way to remodel your brain architecture and use other parts of your brain." [...] "Previous studies have shown that parts of the temporal cortex can be activated by particular object categories in experienced observers -- birds, cars, even Pokemon -- but a limitation of all of those studies is that they only looked after people became experts," says psychologist Patrick Cox, first author of the study. "We measure before and after training, so we can see that extensive training essentially put a category-selective area in the temporal lobe that was not there before." The study culminated in a dual-task experiment, in which the participants were asked to identify cars and take on another challenge. The individuals whose brains had offloaded more car-sorting work to the temporal cortex did better at the second task.

Read more of this story at Slashdot.

A large Danish study found a modest but consistent association between long-term road traffic noise exposure and higher Parkinson's disease risk, with a 3% increase for every 11.5 dB rise in noise at the most exposed side of a home. The Guardian reports: The researchers modeled noise exposure at the most and least exposed exterior of the residence of each participant and calculated the difference in noise levels. The magnitude of the effect was modest but consistent; at the most exposed facade, for every 11.5dB rise in noise level, the risk of Parkinson's disease rose by 3% over the study period. Having a quiet part of the home may mitigate the association between exposure to road traffic noise and higher risk of Parkinson's disease, according to the findings. The study, published in Jama Neurology, included 3.1 million Danish participants aged 40 and over, and followed them for 18 years. It was established using nationwide health register data, making it the largest study on road traffic noise and Parkinson's disease. Previous research linked the rise in neurological disorders, including Parkinson's disease, with exposure to environmental toxins. Environmental risk factors such as air pollution, microplastics and pesticides have become the main focus of prevention strategies. The study is one of the first to make the link to noise pollution.

Read more of this story at Slashdot.

alternative_right shares a report from Phys.org: In a study published in Nature, LSU physicists have developed the first room-temperature quantum material capable of distinguishing and transporting different quantum states of light, overcoming one of the biggest challenges in quantum materials research. Led by Associate Professor of Physics Omar S. Magana-Loaiza, the work establishes a general design principle for engineering an entirely new class of quantum materials, opening new possibilities for quantum computing, secure communications, sensing technologies and advanced energy systems.

Read more of this story at Slashdot.

Astronauts on SpaceX's Fram2 mission successfully captured diagnostic X-ray images in orbit for the first time. The milestone gives space medicine a second imaging option beyond ultrasound and could help future crews diagnose injuries, inspect equipment, and support longer missions to the moon or beyond. Popular Science reports: Commercial off-the-shelf X-ray machines like the ice cooler-sized MinXray TR90BH now allow users to perform scans on subjects far away from traditional facilities. In 2022, [Mayo Clinic researcher Sheyna Gifford] assisted in preparing a crew to successfully generate digital X-rays while experiencing microgravity during a parabolic flight. Gifford's team then spent years collaborating with SpaceX to plan another feasibility study. This time, they didn't want to operate an X-ray machine aboard an aircraft simulating the conditions in space -- they intended to use the equipment during an orbital mission. The process was detailed in a recently published study in the journal Radiology, and focuses on last year's Fram2 mission. Instead of days of medical training, astronauts spent only four hours learning how to use their portable radiography device. They then took preflight X-rays of a hand, forearm, chest, abdomen, and pelvis ahead of their SpaceX Falcon 9 rocket launch on March 31, 2025. Once in orbit, the team calibrated the system before testing their MinXray on the same body parts as well as a smartwatch. Once the crew returned, a trio of independent radiologists reviewed the orbital X-ray images based on their positioning, spatial and contrast resolutions, and general scan quality. Although positioning scores were slightly decreased for the central body images, every other scan held up to similar examples created on Earth. Meanwhile, the astronauts reported that using the machine was easy despite minimal prior coaching. Looking ahead, researchers hope to conduct further X-ray tests during orbital missions, while continuing to reduce the overall size of equipment.

Read more of this story at Slashdot.

Scientists at the Indian Institute of Technology, Madras (IIT-M) have created what they describe as the world's most detailed 3D cellular atlas of the human brainstem, linking whole-brain MRI views to individual neurons across more than 500 tissue sections. The free online atlas, called Anchor, could help researchers better understand diseases such as Alzheimer's, Parkinson's, stroke, and SIDS by showing how healthy and diseased brain tissue differs cell by cell. The BBC reports: Built from high-resolution microscope images rather than costlier molecular techniques, it creates a detailed three-dimensional map of the brainstem, identifying more than 200 clusters of brain cells and nerve pathways. Eight chemical markers help distinguish different cell types, producing one of the clearest pictures yet of this vital, but poorly, understood part of the brain. The brainstem occupies only a sliver of the brain, yet it keeps people alive. It links the brain to the spinal cord and controls breathing, heartbeat, sleep, wakefulness and movement. [...] Users can zoom from the whole brainstem seen on MRI down to individual neurons while maintaining their precise spatial relationships. The researchers have made the atlas freely available online, hoping it becomes a reference tool for neuroscientists, neurologists and neurosurgeons worldwide. Its applications could also extend well beyond anatomy. By comparing healthy brainstem maps with diseased tissue, scientists may better understand disorders ranging from Parkinson's disease and stroke to Alzheimer's disease and sudden infant death syndrome (SIDS). More precise maps could also help neurosurgeons navigate one of the brain's most delicate regions with greater confidence.

Read more of this story at Slashdot.

A new study suggests multilingualism may slow brain aging, with bilingual people showing brains that appear about six years younger than monolingual speakers and people who speak four languages showing brains that appear up to 13 years younger. Researchers say earlier language learning and higher proficiency appear to strengthen the effect. The Guardian reports: Our brains are made up of billions of nerve cells that communicate with one another. But as we get older, the connectivity in our brains often deteriorates, causing memory and speed of thought to decline. While previous research had observed that people from European countries with greater language proficiency tended to age more slowly, this study measured the impact of speaking languages on individual brains. Scientists in Spain, Chile, Argentina and Dublin compared people living in the Basque region -- characterized by high levels of multilingualism -- who spoke Spanish, Basque, French and/or English. To measure neurological age, the scientists used magnetoencephalography to measure the brain activity of 728 people with varying ages and levels of linguistic ability. They then used AI to process the results to calculate a normal level of brain connectivity at any given age. A second unrelated group of 144 people were then scanned and compared, comprising equal numbers of people speaking one, two, three or four languages. Dr Lucia Amoruso, from the Basque Center on Cognition, Brain and Language in San Sebastian, said: "In simple terms, people who spoke more languages tended to have brains that looked younger than expected for their chronological age. The effect was not only related to the number of languages spoken. Higher language proficiency and earlier acquisition of a second language were also associated with more delayed brain ageing. This suggests that multilingual experience matters as a gradient: it is not simply about being bilingual or not, but about the depth and duration of language experience."

Read more of this story at Slashdot.